This page shows the latest mongersen news and features for those working in and with pharma, biotech and healthcare.
The company’s psoriasis drug Otezla is also underperforming, and another blockbuster candidate mongersen failed in phase III.
other pipeline candidates in this therapeutic category including mongersen for inflammatory bowel disease and ozanimod for multiple sclerosis which are both in late-stage testing.
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...